• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 8, 2016

View Archived Issues

Remsima briefing docs suggest FDA comfortable with extrapolation

FDA briefing documents released Friday morning in advance of Tuesday's Arthritis Advisory Committee Meeting suggested the agency will go gentle on the biologics license application for CT-P13, Celltrion Inc.'s biosimilar to Remicade (infliximab, Janssen Biotech Inc.) that is approved elsewhere as Remsima (infliximab). . Read More

TROP-2 it: Moving quickly toward pivotal phase III, Immunomedics vs. TNBC

Looking ahead to the pivotal trial in triple-negative breast cancer (TNBC) with IMMU-132, slated to begin this summer, Immunomedics Inc. stands as "the only game in town at the moment this far along that has an antibody that targets this [TROP-2] receptor," Chau Cheng, director of investor relations, told BioWorld Today. Read More

Sinovac the latest China firm seeking new funds in a bearish market

HONG KONG – Despite a bearish market, biopharma companies in China are looking to tap new funds or investors. And a nascent bidding war for one of the country's best known vaccine makers is a case in point. Read More

Axon regeneration promoted by neuronal activity enhancement

HONG KONG – Neurobiologists at the Hong Kong University of Science and Technology (HKUST) have discovered a novel strategy to promote axon regeneration after central nervous system (CNS) injury, which could lead to the development of potentially clinically useful non-invasive methods to stimulate neuronal activity and eventually the possible repair of spinal injury. Read More

Helomics tumor profiling tech aimed at better drug selection, development

Although definitions of personalized medicine vary greatly from one person and organization to the next, the term gets thrown around a lot in the context of oncology – for good reason. There simply is no one-size-fits-all approach to fighting cancer. Read More

International investors launch funds to tap into Israeli innovation

In previous cycles of interest in the Israeli medical environment, investing in a venture capital vehicle might have been considered the only means to encounter Israeli technologies for financial and perhaps strategic players. That approach has been broadened with many new financial, strategic collaboration approaches available for the world's biomedical-field players to interact and commit to Israel. Venture capitalists from all over the world have come to recognize the value of Israel innovations in the health care sector, and are flocking to invest there. Read More

Financings

Agile Therapeutics Inc., of Princeton, N.J., reported that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 826,771 shares, sold at the public offering price of $6.35 per share. The closing occurred on Feb. 4, bringing the total number of shares sold by Agile in the public offering to about 6.3 million, yielding gross proceeds of about $40.25 million. Net proceeds are expected to be about $37.3 million. William Blair and RBC Capital Markets acted as joint book-running managers, while Janney Montgomery Scott, Cantor Fitzgerald & Co. and FBR Capital Markets acted as co-managers. Read More

Other news to note

Vertex Pharmaceuticals Inc., of Boston, said it received a complete response letter from the FDA for its supplemental new drug application (sNDA) for the use of Kalydeco (ivacaftor) in people with cystic fibrosis (CF), ages 2 and older, who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Read More

In the clinic

Aralez Pharmaceuticals Inc., of Vancouver, British Columbia, disclosed completion of the business combination of Pozen Inc., of Chapel Hill, N.C., and Tribute Pharmaceuticals Canada Inc., of Milton, Ontario. Read More

Bench Press: BioWorld looks at translational medicine

A team from Massachusetts General Hospital has developed a CRISPR-based technique to engineer microdeletions and microduplications. Such microdeletions and microduplications of relatively small stretches of the genome lead to copy number variations (CNVs). Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe